- Home
- PRT vs RPTX Comparison
PRT vs RPTX Comparison
Compare PRT & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRT
- RPTX
- Stock Information
- Founded
- PRT 2017
- RPTX 2016
- Country
- PRT United States
- RPTX Canada
- Employees
- PRT N/A
- RPTX N/A
- Industry
- PRT Oil & Gas Production
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRT Energy
- RPTX Health Care
- Exchange
- PRT Nasdaq
- RPTX Nasdaq
- Market Cap
- PRT 52.2M
- RPTX 54.0M
- IPO Year
- PRT N/A
- RPTX 2020
- Fundamental
- Price
- PRT $4.37
- RPTX $1.29
- Analyst Decision
- PRT
- RPTX Strong Buy
- Analyst Count
- PRT 0
- RPTX 3
- Target Price
- PRT N/A
- RPTX $7.00
- AVG Volume (30 Days)
- PRT 58.4K
- RPTX 232.9K
- Earning Date
- PRT 03-31-2025
- RPTX 03-03-2025
- Dividend Yield
- PRT 9.96%
- RPTX N/A
- EPS Growth
- PRT N/A
- RPTX N/A
- EPS
- PRT 0.42
- RPTX N/A
- Revenue
- PRT $6,059,380.00
- RPTX $66,524,000.00
- Revenue This Year
- PRT N/A
- RPTX $12.15
- Revenue Next Year
- PRT N/A
- RPTX N/A
- P/E Ratio
- PRT $10.29
- RPTX N/A
- Revenue Growth
- PRT N/A
- RPTX 18.19
- 52 Week Low
- PRT $3.26
- RPTX $1.10
- 52 Week High
- PRT $4.64
- RPTX $7.45
- Technical
- Relative Strength Index (RSI)
- PRT 61.17
- RPTX 47.52
- Support Level
- PRT $4.21
- RPTX $1.13
- Resistance Level
- PRT $4.37
- RPTX $1.37
- Average True Range (ATR)
- PRT 0.15
- RPTX 0.09
- MACD
- PRT -0.01
- RPTX 0.04
- Stochastic Oscillator
- PRT 80.26
- RPTX 57.14
About PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive 80% of the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.